Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen ...

Land one of the remote jobs that these companies offer and you’re not likely to ever hear about return-to-office (RTO) ...

Despite resilient demand, healthcare has taken a hit along with the rest of the market. Amgen could boost profits ...

Shares of Amgen Inc. AMGN rose 1.62% to $285.98 Friday, on what proved to be an all-around great trading session for the ...

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with ...

Brokerage customers of the Russian subsidiary of U.S. bank Citi have started receiving coupon payments on securities frozen ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...

In his 13 years as CEO at Amgen, Robert Bradway has seen many of his counterparts at other major biopharma companies come and ...

Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the ...

Amgen (AMGN) stock in focus as Sandoz files antitrust lawsuit alleging that the company blocked copycats from targeting its ...

Jefferies analyst Michael Yee maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $350.00. The company’s ...